<!DOCTYPE html>
<html>
<head>
<title>AF|Rate-Rhythm|RFM 2018</title>
<!-- Global site tag (gtag.js) - Google Analytics -->
<script async src="https://www.googletagmanager.com/gtag/js?id=UA-119340815-7"></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'UA-119340815-7');
</script>

</head>

<meta name="viewport" content="width=device-width, initial-scale=1">
<link rel="stylesheet" href="https://www.w3schools.com/w3css/4/w3.css">
<link href="https://fonts.googleapis.com/css?family=Abel|Michroma|Slabo+27px" rel="stylesheet">
<link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.3.1/css/all.css">

<style>
/*fonts*/
.Abel {font-family: 'Abel', sans-serif;}
.wideFont {font-family: 'Michroma', sans-serif;}
.serif {font-family: 'Slabo 27px', serif;}

/*color*/
.darkRed {color: #420c1a}
.red {color: #883240}
.redBg {background:linear-gradient(to bottom right,#420c1a 0%, #883240 10%,#bd102d 100%)}
.berryRed {color: #bd102d}
.pink {color:#f8e7ea}
.darkBlue {color: #12151f}
.blue2 {color: #627980}
.blue {color: #96a9ae}
.lightBlue {background-color: #fafbfb}

.barContainer {background: #f1f1f1;height: 6vh;width: 100%;position: sticky;top: 0;z-index:3;}
.topBar a {text-decoration: none;font-size: 2.5vh;padding: 1.25vh 0.75vw;font-family: 'Abel', sans-serif}
.header {font-size: 3vh;padding:1vh 1.5vw 0.5vh 0;
    color: #5a5a5a;border-right:#fafbfb solid 0.1vmax}
.fbIcon {font-size: 2.5vh;padding:2.25vh 0.2vw 2.25vh 0.75vw}

@media only screen and (max-width: 1200px) {
    .header {font-size: 2vh;padding: 1vh 1.5vw}
    .topBar a {font-size: 1.8vh;padding: 2vh 1.5vw}
    .fbIcon {font-size: 1.8vh;padding: 2vh 0.5vw}
}
.for900 {display: none}
@media only screen and (max-width:900px) {
    .no900 {display: none}
    .for900 {display: block}
}

.block {
    margin: 3vh 0;position: relative;padding-top:6vh;
}
.blockHolder  {margin: 0 2vw;border-radius: 1vw;}
.topic {font-family: 'Abel', sans-serif;padding:0.75vmax 0.5vmax 0.5vmax 0.75vmax}
.eyebrow {height: 0.5vmax;width: 3vmax;background: linear-gradient(to right, #883240 0%, #bd102d 50%)}
.topicTxt {font-size: 2vmax;color: #96a9ae;line-height: 120%}
.topicTxt :first-child {color:#883240}
.topicTxt :last-child {color: #bd102d}
.headLine {font-family: 'Slabo 27px', serif;color: #12151f;font-size: 2.8vmax;line-height: 120%;
text-align: center}
.imgHolder {max-height: 65vh;max-width: 98%}
@media only screen and (max-width:600px) {
    .blockHolder {margin: 0;border-radius: 0}
    .imgHolder {max-height: auto;max-width:100%}
}
.center {display: block;margin-left: auto;margin-right: auto;}
.ref {font-size: 1vmax;font-family: 'Abel', sans-serif;;color: #96a9ae;
line-height: 120%;margin-top: 0.5vh}
.content {font-size:1.8vmax;line-height: 130%}
.drugTable {font-size: 1.8vmax;line-height: 130%;overflow: scroll;}
.drugTable th, .drugTable td {border: grey 0.1vmax solid;border-collapse: collapse;text-align: center;
                                vertical-align: middle}
.drugTable th:first-child, td:first-child {border-left: none}
.drugTable th:last-child, td:last-child {border-right:none}
.finalList li:hover {font-weight: bold}
.finalList li:first-child:hover {font-weight: 400}
.finalList li {border-radius: 0.5vmax}

/*pointer*/
.pointer {
    cursor: pointer;
    height: 0.5em;
    width: 0.5em;
    margin: 0 0.2em;
    display: inline-block;
    background-color: #fc553d;
    border-radius: 50%;
    position: fixed;  
    z-index: 4;
    animation: blink 1.5s linear infinite;
    }
    @keyframes blink{
    0%{opacity: 0;}
    50%{opacity: 0.7}
    100%{opacity: 1;}
    }

.next {
    position: absolute; display: inline;
    left: 98vw; 
    background-color: transparent;
    color: transparent;
}

</style>

<body>

<!--topBar-->
<div class="barContainer w3-center no900">
    <span class="wideFont header" onclick="unblur()">
        <a href="#top" style="text-decoration:none">Atrial Fibrillation</a></span>
    <span class="topBar" onclick="unblur()">
        <a href="#rate">Rate control</a></span>
    <span class="topBar" onclick="unblur()">
        <a href="#rhythm">Rhythm control</a></span>
    <span class="topBar" onclick="unblur()">
       <a href="#rfm">Risk factors modification</a></span>
    <span class="Abel" onclick="unblur()">
        <a href="https://www.facebook.com/HeartRhythmBox/" title="@heartrhythmbox" target="_blank">
            <i class="fab fa-facebook-square fbIcon" style="color: #3B5998;"></i></a>
        <a href="https://heartrhythmbox.github.io/main/" title="Main Page" target="_blank">
        <img src="box transparent.png" style="width:2.5vh;padding-bottom: 1vh"></a>
    </span>
        
</div>

<!--for mobile-->
<div class="barContainer for900">
    <span class="w3-dropdown-hover" onclick="unblur()" ><i class="fas fa-bars" style="font-size: 2vh;padding: 2vh;
        cursor: pointer;background-color: #f1f1f1;"></i>
        <div class="w3-dropdown-content w3-bar-block w3-card-4 Abel" style="font-size: 2vh">
            <a href="#rate" class="w3-bar-item w3-button">rate control</a>
            <a href="#rhythm" class="w3-bar-item w3-button">rhythm control</a>
            <a href="#rfm" class="w3-bar-item w3-button">risk factors modification</a>
        </div>
    </span>
    <span class="wideFont header" style="border: none" onclick="unblur()">
        <a href="#top" style="text-decoration:none">Atrial Fibrillation</a></span>
    <span class="Abel w3-right" style="padding-right: 1.5vh" onclick="unblur()">
        <a href="https://www.facebook.com/HeartRhythmBox/" title="@heartrhythmbox" target="_blank">
            <i class="fab fa-facebook-square fbIcon" style="color: #3B5998;font-size: 2vh"></i></a>
        <a href="https://heartrhythmbox.github.io/main/" title="Main Page" target="_blank">
        <img src="box transparent.png" style="width:2.2vh;padding-bottom: 1vh"></a>
    </span>
</div>


<!--intro-->
<div class="block" style="padding-top:none">
    <div class="w3-row blockHolder" style="background: black;padding: 3vmax 0vmax">
    <div class="w3-cell w3-cell-middle w3-mobile">
            <video width="100%" height="auto" autoplay muted loop>
                <source src="media/AF LAT.mp4" type="video/mp4">
            </video>
    </div>
    <div class="w3-cell w3-padding w3-cell-middle w3-mobile">
        <img src="media/AF EGM.jpg" style="width: 100%;" class="w3-sepia">
        <img src="media/AF RVR in CHF.jpg" style="width: 100%" class="w3-sepia">
        <div class="w3-container" style="text-align: right;padding-top: 2vh">
            <div class="w3-row wideFont pink" style="font-size: 3.5vmax;">
                Atrial Fibrillation</div>
            <div class="w3-row Abel" style="font-size: 2vmax;color: #b8b8b8">
                rate control | rhythm control | risk factors modification
            <br>
            <a href="https://www.facebook.com/HeartRhythmBox/" title="@heartrhythmbox" target="_blank"
                style="text-decoration:none;font-size: 1.5vmax" class="blue">
            <i class="fab fa-facebook-square blue" style="font-size: 1.5vmax"></i>
            HeartRhythmBox
            </a>
            </div>
        </div>
    </div>
    </div>

    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--pointer-->
<div onclick="pointer()"><span class="pointer" style="display: none"></span>  

<!--rate control-->
<div class="w3-row" id="rate"></div>
<!--rate/why1-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rate control</span>
                <span>&#8765;&thinsp;</span><span class="w3-wide">why</span>
            </div>
        </div>
        <div class="w3-row w3-center w3-white w3-padding" style="margin: 0 0.5vw;">
        <div class="w3-col w3-center s5 w3-padding">
            <img src="media/rate/AF pressure tracing.jpg" style="width:100%">
        </div>
        <div class="w3-col w3-center s7 w3-padding">
            <img src="media/rate/AF hemodynamic.png" style="width:100%"></div>
        </div>
        <div class="w3-row">
            <div class="w3-cell w3-padding w3-cell-middle headLine darkRed" 
            style="font-size:3vmax;text-align: left;line-height: 100%">
                <span class="w3-wide red">Rate</span><br>Control</div>
            <div class="w3-cell w3-padding Abel blue2 w3-cell-middle" style="font-size:2vmax">
                ..reduces symptoms and improves hemodynamic.<br>
                ..is an essential therapy of AF regardless of whether rhythm or rate control strategy is chosen.
            </div>
        </div>
        
        <div class="ref w3-center">
            <a href="https://www.sciencedirect.com/science/article/pii/S0002914902033738?via%3Dihub#BIB35" 
            target="_blank">
                Maisel and Stevension. Am J Cardiol. 2003 Mar 20;91(6A):2D-8D.</a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>


<!--Rate Why2-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rate control</span>
                <span>&#8765;&thinsp;</span><span class="w3-wide">why</span>
            </div>
        </div>
        <div class="w3-row">
            <div class="w3-col s7 w3-center w3-padding w3-mobile">
            <img src="media/rate/TachyMyopathyMech.jpg" class="imgHolder"></div>
            <div class="w3-col s5 w3-padding headLine darkRed w3-mobile" style="text-align:left;line-height: 140%">
            AF is the most common arrhythmic cause of tachycardia induced cardiomyopathy.<br>
            Rate control, as well as rhythm control, is shown to reverse the process.
                <div class="ref">
                <a target="_blank"
                href="https://www.sciencedirect.com/science/article/pii/S0735109715049980?via%3Dihub#bib55">
                Gopinathannair et al. J Am Coll Cardiol. 2015 Oct 13;66(15):1714-28.</a></div>
            </div>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--rate/how agent bb ccb-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rate control</span>
                <span>&#8765;&thinsp;</span><span class="w3-wide">how</span>
            </div>
        </div>
        <div class="w3-cell-row w3-padding">
            <div class="w3-cell w3-cell-middle w3-padding">
                <img src="media/rate/AcuteRate.png" style="width:100%"></div>
            <div class="w3-cell w3-cell-middle w3-padding">
                <img src="media/rate/ChronicRate.png" style="width:100%">
                <div class="ref">
                    <a href="https://academic.oup.com/eurheartj/article/37/38/2893/2334964" target="_blank">
                    2016 ESC Guidelines for AF
                    </a>
                </div>
            </div>
        </div>
        <div class="w3-container w3-padding headLine darkRed" style="text-align:left">
            Choice of rate-controlling agents depend on LVEF.</div>
        <div class="w3-row w3-padding Abel blue2 content">
            CCB is not recommended in a patient with heart failure or impaired LV function. <br>
            The role of digoxin as the first line is limited due to the inefficacy at controlling ventricular rate
            during exercise.<br>
            May use amiodarone for rate control in acute setting; but not in a long-term.</span>
        </div>
        
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--rate/how/dig mortality-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rate control</span>
                <span>&#8765;&thinsp;</span><span class="w3-wide">how</span>
                <span>- digoxin</span>
            </div>
        </div>
        <img src="media/rate/dig.png" class="imgHolder center">
        <div class="w3-container w3-center w3-padding headLine darkRed" style="text-align:left">
            Digoxin may increase mortality in AF.</div>
        <div class="w3-row w3-padding Abel blue2" style="font-size:1.8vmax">
            Data from Aristotle showed that in patients with AF currently taking digoxin, 
            the risk of death was independently related to serum digoxin concentration; 
            highest with concentrations ≥1.2 ng/ml.<br>
            The risk of death was greatest early after initiation of digoxin in 
            previous nonusers, particularly with respect to sudden cardiac death.
        </div>
        <div class="ref" style="padding-left:1vmax">
            <a href="https://www.sciencedirect.com/science/article/pii/S0735109718301037?via%3Dihub" target="_blank">
            Lopes et al. J Am Coll Cardiol. 2018 Mar 13;71(10):1063-1074.</a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--rate/avn abl-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rate control</span>
                <span>&#8765;&thinsp;</span><span class="w3-wide">how</span>
            </div>
        </div>
        <div class="w3-row">
            <div class="w3-col s4 w3-padding w3-mobile">
                <img src="media/rate/AVNodalAbl.jpg" style="width:100%"></div>
            <div class="w3-col s8 w3-mobile">
                <div class="w3-container w3-padding headLine darkRed" style="text-align:left">
                AV nodal ablation</div>
            <ul class="w3-ul w3-hoverable Abel blue2" style="font-size:1.8vmax">
            <li class="w3-hover-light-grey">Last resource for those who were UNRESPONSIVE or INTOLERANT to INTENSIVE rate/rhythm control.</li>
            <li class="w3-hover-light-grey">Remember that the patient will be pacemaker dependent for the rest of his life.</li>
            <li class="w3-hover-light-grey">Consider CRT; rather than a simple pacemaker, in a patient with impaired LVEF.</li>
            <li class="w3-hover-light-grey">Sudden cardiac arrest may occur early after AV nodal ablation due to abrupt change in heart rate,
                sympathetic tone, and K-channel function. Rapid pacing during the first few months reduces the incidence of
                SCA.</li>
            </ul>
            <div class="ref" style="text-align:center">
                <a href="https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000041" target="_blank">
                    2014 ACC Guideliens for AF</a> and
                <a href="https://academic.oup.com/eurheartj/article/37/38/2893/2334964" target="_blank">
                    2016 ESC Guidelines for AF
                </a>
            </div>
            </div>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--rate/how target-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rate control</span>
                <span>&#8765;&thinsp;</span><span class="w3-wide">how</span>
            </div>
        </div>
        <div class="w3-row">
            <div class="w3-col s6 w3-padding"><img src="media/rate/RACEII.png" style="width:100%"></div>
            <div class="w3-col s6 w3-padding"><img src="media/rate/rateInHFrEF.png" style="width:100%"></div>
        </div>
        <div class="w3-container w3-padding headLine darkRed" style="text-align:left">
            Target Resting Heart Rate is &lt;110 bpm for the majority of the AF patients including 
            those with HFrEF.</div>
        <div class="ref" style="padding-left: 1vmax">Ref: 
            <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1001337" target="_blank">RACEII</a>,
            <a href="https://onlinelibrary.wiley.com/doi/abs/10.1093/eurjhf/hft093" target="_blank">RACEII - post Hoc</a>,
            &nbsp;and <a target="_blank"
            href="https://www.sciencedirect.com/science/article/pii/S0735109717368936?via%3Dihub">
            Beta-Blockers in Heart Failure.</a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--rate/remark on very high rate-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rate control</span>
                <span>&#8765;&thinsp;</span><span class="w3-wide">remark</span>
            </div>
        </div>
        <img src="media/rate/AF with wpw 004.png" class="imgHolder center" style="width:auto;">
        <div class="w3-container w3-center w3-padding headLine darkRed" style="text-align:left">
            In a patient with AF with extremely rapid ventricular rate, think of...</div>
        <div class="w3-row w3-center w3-padding Abel blue2" style="font-size:1.8vmax">
            pre-excitation (WPW), hyperthyroidism, or catecholiminergic surge.
        </div>
        
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<div id="rhythm" class="w3-row w3-padding"></div>
<!--rhythm/why1-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rhythm control</span>
                <span>&#8765;&thinsp;</span><span class="w3-wide">why</span>
            </div>
        </div>
        <img src="media/rhythm/AF with STEMI.jpg" class="imgHolder center" style="width:auto;">
        <div class="w3-container w3-center w3-padding headLine darkRed" style="text-align:left">
            Rhythm control saves life in an emergent situation such as...</div>
        <div class="w3-row w3-center w3-padding Abel blue" style="font-size:1.8vmax">
            AF with WPW, acute myocardial ischemia, acute pulmonary edema, or unstable hemodynamic situation.
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--rhythm/why2-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rhythm control</span>
                <span>&#8765;&thinsp;</span><span class="w3-wide">why</span>
            </div>
        </div>
        <div class="w3-padding imgHolder">
            <div class="w3-col s4 w3-padding">
                <img src="media/rhythm/CameraMriLvef.png" style="width:100%"></div>
            <div class="w3-col s8 w3-padding">
                <img src="media/rhythm/CastleAfPrimaryOutcome.png" style="width:100%">
            </div>
        </div>
        <div class="w3-container w3-padding headLine darkRed" style="text-align:left">
            Rhythm control improves LV function, and cardiovascular outcomes in selected 
            populations.</div>
        <div class="ref" style="padding-left: 1vmax">Ref:
            <a href="https://www.sciencedirect.com/science/article/pii/S073510971739349X?via%3Dihub" target="_blank">
            CAMERA-MRI</a> and 
            <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1707855" target="_blank">CASTLE-AF</a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--rhythm/whom rate vs rhythm-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rhythm control</span>
                <span>&#8765;&thinsp;</span><span class="w3-wide">why</span>
                <span>- vs. rate control</span>
            </div>
        </div>
        <img src="media/rhythm/AFFIRM SR.png" class="imgHolder center">
        <div class="w3-container w3-padding headLine darkRed" style="text-align:left">
            Being in sinus rhythm is the best but how to get there is not easy.</div>
        <div class="w3-row w3-padding Abel blue2" style="font-size:1.8vmax">
            In AFFIRM, rhythm control was not superior to rate control in mortality, CV outcome, or quality of life
            in an intention-to-treat analysis. On-treatment analysis, however, showed the mortality benefit of
            being in sinus rhythm was associated with a lower risk of death, while AAD use was associated with 
            increased risk of death.
        </div>
        <div class="ref" style="padding-left: 1vmax">
            <a href="https://www.ahajournals.org/doi/abs/10.1161/01.cir.0000121736.16643.11" target="_blank">
                AFFIRM Investigators. Circulation. 2004;109:1509–1513.</a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--rhythm/whom rate vs rhythm-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rhythm control</span>
                <span>&#8765;&thinsp;</span><span class="w3-wide">why</span>
                <span>- vs. rate control</span>
            </div>
        </div>
        <img src="media/rhythm/Rate Rhythm Algorithm CCS guidelines.jpg" class="imgHolder center" style="padding-top: 2vmax">
        <div class="w3-container w3-padding headLine darkRed" style="text-align:left">
            Choosing rhythm or rate control strategy is not a one-way task. You can always change your mind.</div>
        <div class="w3-row w3-padding Abel blue2" style="font-size:1.8vmax">
            For most patients, rate control seems to be the first appropriate step.<br>
            In selected cases with highly symptomatic AF or arrhythmia induced cardiomyopathy, 
            early consideration of rhythm control in conjunction with rate control might be indicated. 
        </div>
        <div class="ref" style="padding-left: 1vmax">
            <a href="https://www.onlinecjc.ca/article/S0828-282X(14)01249-5/abstract" target="_blank">
            2014 CCS Guidelines for AF</a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--rhythm/how cv-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rhythm control</span>
                <span>&#8765;&thinsp;</span><span class="w3-wide">how</span>
            </div>
        </div>
        <div class="w3-row w3-padding">
            <div class="w3-col s5 w3-mobile w3-padding">
                <img src="media/rhythm/DefibPad.png" style="width: 100%">
                <div class="ref w3-center" style="padding-bottom:0.5vmax">
                    <a href="https://www.zoll.com/medical-products/product-manuals">
                    Zoll - Product Manuals</a>
                </div>
            </div>
            <div class="w3-col s7 w3-mobile w3-padding redBg">
            <div class="w3-container w3-padding headLine" style="text-align:left;color:#f8e7ea">
            Synchronized Cardioversion</div>
            <ul class="w3-ul w3-hoverable w3-padding Abel" style="font-size:1.8vmax;color: #fafbfb">
            <li class="w3-hover-light-grey">Method of choice to restore sinus rhythm in an emergent situation.</li>
            <li class="w3-hover-light-grey">Anterior-posterior pad position is more effective than antero-lateral position.</li>
            <li class="w3-hover-light-grey">Unless the patient has been adequately anticoaguated at least 3wks prior, immediate anticoagulation
                is required before cardioversion.</li>
            <li class="w3-hover-light-grey">Anticoagulation should be continued for at least 3wks after cardioversion, and lifelong in patients 
                at risk of stroke.</li>
            </ul>
            <div class="ref w3-center">
            <a href="https://academic.oup.com/eurheartj/article/37/38/2893/2334964#110288901" target="_blank">
            2016 ESC Guidelines for AF</a> and
            <a href="https://www.sciencedirect.com/science/article/pii/S0140673602113158?via%3Dihub#bib8" target="_blank">
            Kirchof et al. Lancet 2002;26:1275-79.</a>
            </div>
            </div>
            
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--rhythm/how/AAD-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rhythm control</span>
                <span>&#8765;&thinsp;</span><span>how</span>
            </div>
        </div>
        <div class="imgHolder center w3-responsive" style="border: #883240 0.1vmin solid;max-height: 50vh">
            <table class="w3-table Abel drugTable">
            <tr class="redBg pink">
                <th>Agents</th><th>Acute Conversion (&lt;7d)</th><th>Chronic Conversion (>7d)</th>
                <th>LVH</th><th>CAD</th><th>CHF</th>
                <th>AV node blocking property</th><th>ECG features prompting discontinuation</th>
            </tr>
            <tr>
                <td>Flecainde</td><td>Y</td><td>N</td><td>N</td><td>N</td><td>N</td>
                <td>None</td>
                <td>QRS>25% wider</td>
            </tr>
            <tr>
                <td>Propafenone</td><td>Y</td><td>N</td><td>N</td><td>N</td><td>N</td>
                <td>Minimal</td>
                <td>QRS>25% wider</td>
            </tr>
            <tr>
                <td>Amiodarone</td><td>Y</td><td>Y</td><td>Y</td><td>Y</td><td>Y</td>
                <td>Moderate</td>
                <td>QTc>500ms</td>
            </tr>
            <tr>
                <td>Dronedarone</td><td>N</td><td>N</td><td>Y</td><td>Y</td><td>Y for mild form</td>
                <td>Moderate</td>
                <td>QTc>500ms</td>
            </tr>
            <tr>
                <td>Sotalol</td><td>N</td><td>N</td><td>N</td><td>Y</td><td>N</td>
                <td>A lot</td>
                <td>QTc>500ms or QTc increases >60ms</td>
            </tr>
            <tr>
                <td>Ibutilide (IV)</td><td>Y</td><td>Y</td><td colspan="3">Careful</td>
                <td>None</td>
                <td>Careful in long QTc</td>
                </tr>
            <tr>
                <td>Vernakalant (IV)</td><td>Y</td><td>N</td><td>Y</td><td>Y for stable CAD</td><td>Y for mild form</td>
                <td>Moderate</td>
                <td>Avoid in QTc>440</td>
                </tr>
            </table>
        </div>
        <div class="w3-container w3-padding headLine darkRed" style="text-align:left">
            Antiarrhythmic Drugs (AADs)</div>
        <div class="w3-row w3-padding Abel blue2" style="font-size:1.8vmax">
            The choice of the agent depends largely on the presence of structural heart diseases.<br>
            Avoid IC agents (Flecainide and Propafenone) in a patient with structural heart disease.<br>
            Avoide Dronedarone in moderate to severe heart failure.<br>
        </div>
        <div class="ref" style="padding-left: 1vmax">
            <a href="https://academic.oup.com/eurheartj/article/37/38/2893/2334964#110288901" target="_blank">
                2016 ESC Guidelines for AF</a> and
            <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101194/" target="_blank">
                Camm J. Curr Cardiol Rev. 2014 Nov; 10(4): 309–314.</a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--rhythm/how/IC se-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rhythm control</span>
                <span>&#8765;&thinsp;</span><span>how</span>
                <span>&#8765;&thinsp;</span><span class="w3-wide">AAD - IC</span>
            </div>
        </div>
        <img src="media/rhythm/AFL from IC.png" class="imgHolder center">
        <div class="w3-container w3-center w3-padding headLine darkRed" style="text-align:left">
            Class IC AADs have minimal to none of beta blocking property.</div>
        <div class="w3-row w3-padding Abel blue2" style="font-size:1.8vmax">
            What that means is...if the drug turn AF into atrial flutter, without beta blocking
            property, the patient may develop atrial flutter with 1:1 AV conduction. So...
            when prescribes flecainide or propafenone, remember to add beta blocker to the regimen,
            unless you really really have good enough reasons not to.
        </div>
        
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--rhythm/how/cordarone -->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rhythm control</span>
                <span>&#8765;&thinsp;</span><span>how</span>
                <span>&#8765;&thinsp;</span><span class="w3-wide">AAD - Amiodarone</span>
            </div>
        </div>
        <div class="w3-row">
            <div class="w3-col w3-padding m5 l5 w3-mobile">
            <img src="media/rhythm/amiodarone.png" style="width:100%;"></div>
            <div class="w3-col w3-padding m7 l7 w3-mobile">
            <img src="media/rhythm/corneal deposit.jpeg" style="width:50%;">
            <div class="w3-container headLine darkRed" style="text-align:left">
                    Amiodarone side effects</div>
                <div class="w3-row w3-padding Abel blue2" style="font-size:1.8vmax;text-align: left">
                    <div class=" w3-hover-light-grey" style="border-bottom:#96a9ae 0.1vmin solid"> The prevalence of adverse effects related to treatment with amiodarone
                        is 15% the first year and 50% in case of prolonged administration.</div>
                    <div class=" w3-hover-light-grey" style="border-bottom:#96a9ae 0.1vmin solid">Higher dose (ie.&ge;400mg/day) is related to higher incidence of side effects
                        esp. lung toxicity.</div>
                    <div class=" w3-hover-light-grey">
                        Cornea microdeposits (shown in above image) are found in nearly all patients
                        receiving amiodarone for more than 6 months. Unlike optic neuritis, their presence does not require 
                        withdrawal of treatment, since they are not related to impairment of visual acuity.</div>
                </div>
                <div class="ref" style="padding-left:1vmax">Ref:
                    <a target="_blank"
                    href="https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-10/Treatment-with-amiodarone-How-to-avoid-complications">
                        Merino and Perez de Isla. ESC E-Journal of Cardiology Practice 2011.
                        </a> and 
                    <a href="https://www.nejm.org/doi/full/10.1056/NEJMicm1406501" target="_blank">
                        Chan and Jhanji. N Engl J Med 2015; 372:1656</a>
                </div>
            </div>
        </div>
        
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--rhythm/how/ablation -->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rhythm control</span>
                <span>&#8765;&thinsp;</span><span>how</span>
                <span>&#8765;&thinsp;</span><span>Ablation</span>
            </div>
        </div>
        <div class="w3-responsive" style="padding: 1vmax;border:#420c1a 1vmax solid">
            <table class="w3-table w3-bordered w3-hoverable w3-centered Abel" style="font-size:2vmax">
            <tr>
                <th>Setting</th><th>Line of therapy</th><th>Class of recommendation</th>
            </tr>
                <tr class="w3-hover-yellow">
                <td>Symptomatic Paroxysmal</td>
                <td>First Line</td>
                <td>IIa</td>
            </tr>
            <tr class="w3-hover-green">
                <td>Symptomatic Paroxysmal</td>
                <td>Second Line</td>
                <td>I</td>
            </tr>
            <tr class="w3-hover-yellow">
                <td>Symptomatic Persistent</td>
                <td>Second Line</td>
                <td>IIa</td>
                </tr>
            <tr class="w3-hover-yellow">
                    <td>Symptomatic Long-persistent</td>
                    <td>Second Line</td>
                    <td>IIa (IIb in 2014 ACC)</td>
                </tr>
            <tr class="w3-hover-yellow">
                    <td>Symptomatic HFrEF</td>
                    <td>suspected tachycardia induced cardiomyopathy</td>
                    <td>IIa</td>
                    </tr>
            <tr class="w3-hover-yellow">
                    <td>AF related tachycardia</td>
                    <td>to avoid pacemaker implantation</td>
                    <td>IIa</td>
                    </tr>
        </table></div>
        <div class="w3-container w3-padding headLine darkRed" style="text-align:left">
            Catheter ablation: current recommendation.</div>
        <div class="w3-row w3-padding Abel blue2" style="font-size:1.8vmax">
            Catheter Ablation reduces symptoms, improves quality of life, increases time
            in sinus rhythm, and increases LVEF in HFrEF when compared to AADs.
            Additionally, a recent RCT showed mortality benefit of catheter ablation in AF with 
            HFrEF.
        </div>
        <div class="ref" style="padding-left: 1vmax">
            <a href="https://academic.oup.com/eurheartj/article/37/38/2893/2334964#110288901" target="_blank">
            2016 ESC Guidelines for AF</a>, 
            <a href="https://jamanetwork.com/journals/jama/fullarticle/185277" target="_blank">Thermocool-AF</a>,
            <a href="https://jamanetwork.com/journals/jama/fullarticle/1829990" target="_blank">RAFFT-2</a>, 
            <a href="https://www.ahajournals.org/doi/full/10.1161/CIRCEP.114.001938" target="_blank">Meta-Analysis in HFrEF</a>,
            and <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1707855" target="_blank">CASTLE-AF.</a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--rhythm/how/ablation CAMERA-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rhythm control</span>
                <span>&#8765;&thinsp;</span><span>how</span>
                <span>&#8765;&thinsp;</span><span class="w3-wide">Ablation - CAMERA-MRI</span>
            </div>
        <div class="w3-row" style="padding:2vmax 0.2vmin 0.2vmin 1vmax">
            <div class="w3-col l4 m6 s6 w3-padding">
                <img src="media/rhythm/CameraMriLvef.png" style="width:100%">
            </div>
            <div class="w3-col l4 m6 s6 w3-padding">
                <img src="media/rhythm/CameraMriLge.jpg" style="width:100%">
            </div>
            <div class="w3-col l4 m12 s12">
            <div class="w3-container w3-padding headLine darkRed" style="text-align:left">
                Catheter ablation in persistent AF with idiopathic cardiomyopathy.</div>
            <div class="w3-row w3-padding Abel blue2" style="font-size:1.8vmax">
                The restoration of sinus rhythm with catheter ablation results in significant improvement of LVEF,
                particularly in the absence of ventricular fibrosis on CMR.
            </div>
            <div class="ref" style="padding-left: 1vmax">
                <a href="https://www.sciencedirect.com/science/article/pii/S073510971739349X?via%3Dihub" target="_blank">
                CAMERA-MRI</a>
            </div></div>
        </div>
        </div>
        
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--rhythm/how/ablation Castle-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>rhythm control</span>
                <span>&#8765;&thinsp;</span><span>how</span>
                <span>&#8765;&thinsp;</span><span class="w3-wide">Ablation - CASTLE-AF</span>
            </div>
        </div>
        <div class="w3-row" style="padding-top: 1vmax">
            <div class="w3-col s5 w3-padding">
                <img src="media/rhythm/CastleAfPrimaryOutcome.png" style="width:100%">
            </div>
            <div class="w3-col s7 w3-padding">
                <img src="media/rhythm/CastleAFTable.jpeg" style="width:100%">
            </div>

        </div>
        <div class="w3-container w3-padding headLine darkRed" style="text-align:left">
            CASTLE-AF: the first RCT that showed benefits of catheter ablation on CV outcomes.</div>
        <div class="w3-row w3-padding Abel blue2" style="font-size:1.8vmax">
            Catheter ablation for atrial fibrillation in patients with heart failure was 
            associated with a significantly lower rate of a composite end point of death from
            any cause or hospitalization for worsening heart failure than was medical therapy. 
        </div>
        <div class="ref" style="padding-left: 1vmax">
            <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1707855" target="_blank">CASTLE-AF.</a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<div class="w3-row" id="rfm"></div>
<!--RFM1-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>risk factors modification</span>
                <span>&#8765;&thinsp;</span><span>why</span>
            </div>
        </div>
        <div class="w3-row imgHolder w3-padding">
            <div class="w3-col s5 w3-padding">
                <img src="media/RFM/obesityMech.jpg" style="width:100%">
            </div>
            <div class="w3-col s7 w3-padding">
                <img src="media/RFM/overview.jpg" style="width:100%">
            </div>
        </div>
        <div class="w3-container w3-padding headLine darkRed" style="text-align:left">
            Risk Factors Modification (RFM)</div>
        <div class="w3-row w3-padding Abel blue2" style="font-size:1.8vmax">
            Cardiometabolic risk factors such as obesity, physical inactivity, hypertension,
            DM, and dyslipidemia have all been linked to increased incidence of AF.
            
        </div>
        <div class="ref" style="padding-left: 1vmax">
            <a href="https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000568" target="_blank">
            AHA Scientific Statement on AF Burden</a> and
            <a href="https://www.sciencedirect.com/science/article/pii/S0735109717395694?via%3Dihub" target="_blank">
            Lavie et al. JACC 2017;70:2022-35.</a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--RFM2-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>risk factors modification</span>
            </div>
        </div>
        <div class="w3-row imgHolder w3-padding">
            <div class="w3-col s5" style="padding: 0 0.1vmax">
                <img src="media/RFM/outcomeRFM.png" style="width:100%">
            </div>
            <div class="w3-col s7" style="padding: 0 0.1vmax">
                <img src="media/RFM/exercise and AF burden RCT.png" style="width:100%">
            </div>
        </div>
        <div class="w3-container w3-padding headLine darkRed" style="text-align:left">
            Risk Factors Modification (RFM)</div>
        <div class="w3-row w3-padding Abel blue2" style="font-size:1.8vmax">
            Data from a small RCT and several non-RCTs showed that comprehensive risk factors management
            is effective in reducing AF burden, improving LA and LV function, and increasing quality of life.    
        </div>
        <div class="ref" style="padding-left: 1vmax">
            <a href="http://electrophysiology.onlinejacc.org/content/early/2017/03/24/j.jacep.2016.12.015" target="_blank">The CENT Study</a>, 
            <a href="http://www.onlinejacc.org/content/65/20/2159" target="_blank">LEGACY Study</a>, 
            and <a href="https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.115.018220" target="_blank">
                Circulation. 2016;133:466-473. </a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--latest trial Ablate and Pace-->
<div class="block">
    <div class="blockHolder lightBlue">
        <div class="w3-row topic">
            <div class="eyebrow"></div>  
            <div class="topicTxt">
                <span>latest trial</span>
                <span>&#8765;&thinsp;</span><span>APAF-CRT</span>
                
            </div>
        </div>
        <div class="w3-row" style="padding-top: 1vmax">
            <img src="media/APAF CRT.png" class="imgHolder center">            

        </div>
        <div class="w3-container w3-padding headLine darkRed" style="text-align:left">
            APAF-CRT: 'Ablate and Pace' for permanent AF with heart failure and narrow QRS.</div>
        <div class="w3-row w3-padding Abel blue2" style="font-size:1.8vmax">
            In an elderly patient (mean age=72) with severely symptomatic permanent AF unsuitable or failed AF ablation,
            narrow QRS, and at least one HF hospitalization in the previous year, AV junction ablation + CRT was 
            superior to pharmacological therapy in reducing HF symptoms and hospitalization.
        </div>
        <div class="ref" style="padding-left: 1vmax">
            <a href="https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehy555/5078460?redirectedFrom=fulltext" 
            target="_blank">APAF-CRT.</a>
        </div>
    </div>
    <div class="w3-btn next" onmouseover="blockNav(1)"></div>
</div>

<!--conclusions-->
<div class="block">
    <div class="blockHolder lightBlue">
        <ul class="w3-ul Abel finalList" style="font-size:2vmax;padding:1vmax">
            <li class="wideFont w3-white darkBlue" style="font-size:2.5vmax;">CONCLUSIONS</li>
            <li style="background:#f8e7ea">
            Rate control is an essential part throughout the life of the patient regardless of 
            the treatment strategy.</li>
            <li style="background:#bd102d;color:white">In selected cases with highly symptomatic AF or arrhythmia induced cardiomyopathy, 
                consider rhythm control in conjunction with rate control.</li>
            <li style="background:#883240;color:white">Catheter ablation in HFrEF is associated with improved mortality and HF hospitalization.</li>
            <li style="background:#420c1a;color:white">Physical activity and weight control is effective in reducing AF burden.</li>
            
        </ul>
    </div>
</div>



<!--end pointer-->

<!--end page-->
<div class="w3-container Abel w3-center" 
style="margin-top:10vh;background:#f1f1f1;font-size: 1vmax;padding: 2vmax;color:#797979">
    <a href="#top" style="font-size:1.5vmax;text-decoration: none" title="to top" onclick="unblur()">
        <i class="fas fa-arrow-circle-up"></i></a><br>
    HeartRhythmBox, an education page of heart rhythm topics.<br>
    visit us at <a href="https://heartrhythmbox.github.io/main/" target="_blank">
    https://heartrhythmbox.github.io/main/</a><br>
    or <a href="https://www.facebook.com/HeartRhythmBox/" target="_blank">https://www.facebook.com/HeartRhythmBox/</a>
</div>


</div>

<script src="block navigation.js"></script>
<script>

window.addEventListener("keydown", function(event) {
        event.preventDefault();
        if (event.keyCode===32) {
        var p = document.getElementsByClassName("pointer");
        p[0].style.display = "none";}
    })

window.addEventListener("keydown", function(event) {
        event.preventDefault();
        if (event.keyCode===27) {
        window.unblur()}
    })

//up arrow
window.addEventListener("keydown", function(event) {
    event.preventDefault();
    if (event.keyCode===38) {
    blockNav(-1)}
})
//down arrow
window.addEventListener("keydown", function(event) {
    event.preventDefault();
    if (event.keyCode===40) {
    blockNav(1)}
})

window.ontouchmove = function () {unblur()};

//pointer
function pointer() {
    var x = event.clientX;
    var y = event.clientY;
    var p = document.getElementsByClassName("pointer");
    p[0].style.display = "inline";
    p[0].style.left = x+"px"; 
    p[0].style.top = y+"px";
    }

function unblur() {
    var b = document.getElementsByClassName("block");
    var i;
    for (i=0;i<b.length;i++){
        b[i].style.opacity = 1;
    }
}


</script>


</body>
</html>